InsiderTrades.com logo
“Retirement Secret” Showed 995% Gain Last Time We Shared It
From Stansberry Research   |   Ad
Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.
Find out why right here (and see what you can do to get in too with just a few dollars).

L. Smith Biography and Net Worth

Insider of Alzamend Neuro
  • Phone
  • Website


L. Smith is the Insider of Alzamend Neuro.

How do I contact L. Mary Smith?

The corporate mailing address for Smith and other Alzamend Neuro executives is , , . Alzamend Neuro can also be reached via phone at 844-722-6303. Learn More on L. Mary Smith's contact information.

Has L. Mary Smith been buying or selling shares of Alzamend Neuro?

L. Mary Smith has not been actively trading shares of Alzamend Neuro in the last ninety days. Learn More on L. Mary Smith's trading history.

Who are Alzamend Neuro's active insiders?

Alzamend Neuro's insider roster includes Milton Ault III (Major Shareholder), Milton Ault, III (Major Shareholder), Milton Ault, III. (Major Shareholder), Mark Gustafson (Director), and L. Smith (Insider). Learn More on Alzamend Neuro's active insiders.

Are insiders buying or selling shares of Alzamend Neuro?

During the last year, Alzamend Neuro insiders bought shares 8 times. They purchased a total of 14,233 shares worth more than $47,391.59. The most recent insider tranaction occured on April, 19th when Director Milton C Ault III bought 1,000 shares worth more than $690.00. Insiders at Alzamend Neuro own 10.9% of the company. Learn More about insider trades at Alzamend Neuro.

Information on this page was last updated on 4/19/2024.

L. Mary Smith Insider Trading History at Alzamend Neuro

See Full Table

L. Mary Smith Buying and Selling Activity at Alzamend Neuro

This chart shows L. Mary Smith's buying and selling at Alzamend Neuro by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alzamend Neuro Company Overview

Alzamend Neuro logo
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Read More

Today's Range

Now: $0.70
Low: $0.70
High: $0.73

50 Day Range

MA: $0.92
Low: $0.68
High: $1.20

2 Week Range

Now: $0.70
Low: $0.65
High: $11.91

Volume

25,277 shs

Average Volume

52,212 shs

Market Capitalization

$4.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.02
“Retirement Secret” Showed 995% Gain Last Time We Shared It
From Stansberry Research   |   Ad
Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.
Find out why right here (and see what you can do to get in too with just a few dollars).